Skip to main content

Table 4 Progression-free survival/multivariate analysis/

From: Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy

Factor

Variant

Cases n (%)

HR (±95% CI)

P

Histotype

Non-serous

57 (44.2)

1 (ref)

 

Serous

72 (55.8)

5.04 (2.05-12.37)

0.0004

FIGO

1 + 2

58 (46.0)

1 (ref)

 

3 + 4

68 (54.0)

2.19 (1.03-4.64)

0.041

ABCB1 p.Ser893Ala p.Ser893Thr rs2032582

Common allele carriers (GG + GT + GA)

101 (80.2)

1 (ref)

 

Rare genotypes (AT + TT)

25 (19.8)

2.14 (1.07-4.28)

0.031

ATM p.Asp1853Asn rs1801516

Rare allele carriers (GA + AA)

87 (61.0)

1 (ref)

 

Common homozygote (GG)

39 (39.0)

2.32 (1.06-5.10)

0.036

  1. Statistically significant analyses are in bold.